Equity Overview
Price & Market Data
Price: $0.96
Daily Change: -$0.0799 / 8.32%
Range: $0.92 - $1.09
Market Cap: $54,207,724
Volume: 67,395
Performance Metrics
1 Week: -6.79%
1 Month: 6.34%
3 Months: 28.91%
6 Months: -1.02%
1 Year: -76.12%
YTD: -24.70%
Company Details
Employees: 131
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein for the treatment of advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion; PRT7732, a selective and orally bioavailable SMARCA2 degraders to treat advanced or metastatic solid tumors; and PRT2527, a cyclin-dependent kinase 9 inhibitor for the treatment of advanced solid tumors. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC, and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.